Cytokinetics EVP Malik Fady Ibraham Exercises Options and Sells Shares at $86.62

On July 7, 2026, Malik Fady Ibraham, Executive Vice President of Research & Development at Cytokinetics Inc, executed a series of stock transactions. He exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share, acquiring 3,500 common shares through this option exercise. Subsequently, on the same day, he sold 3,500 common shares at $86.62 per share, resulting in total proceeds of approximately $303,170 from the sale. Following these transactions, Ibraham's direct ownership position in Cytokinetics common stock decreased from 157,402 shares to 153,902 shares. He retains 37,386 unexercised stock options. The transactions represent a typical executive compensation realization strategy, exercising in-the-money options and selling a portion of the acquired shares, likely for diversification or liquidity purposes.